Vol. 20/No. 22 | Oncology Live®

November 21, 2019

Allison Campbell, MD, PhD, discusses the synergy between immune checkpoint inhibitors and radiation therapy and the challenges facing ongoing clinical development.

November 20, 2019

A growing appreciation of the immunomodulatory properties of radiation therapy (RT) and their role in the rare, but highly sought-after “abscopal effect”—whereby localized RT elicits systemic antitumor effects—is fueling excitement in the radiation oncology field.

November 19, 2019

Although the oncology community has made many advancements in understanding the role of germline mutations in prostate cancer, a pressing need exists for clarity in determining which genes should be included in testing panels and what steps should be taken to counsel patients at risk and their families.

November 19, 2019

Updated venous thromboembolism (VTE) guidelines issued by the American Society of Clinical Oncology now include the use of direct oral anticoagulants for patients with cancer as a preventive measure against VTE recurrence.

November 18, 2019

In a phase III trial, investigators are examining if arfolitixorin can supplant leucovorin calcium, a widely used component of combination regimens in patients with metastatic colorectal cancer.

November 18, 2019

The number of new therapies that have shown singleagent activity in metastatic disease, the earlier use of immune checkpoint blockade, and our continued attempts to refine our knowledge of the pathogenesis of urothelial carcinoma are expected to dramatically change treatment algorithms and outcomes over the next 5 to 10 years.

November 16, 2019

A large proportion of medical waste in oncology is considered hazardous and must be disposed of correctly.

November 15, 2019

Although use of wearable mobile health monitors has soared in other fields of healthcare, adoption of these electronic devices has lagged in oncology.

November 14, 2019

The slate of biosimilars for cancer is growing, and with this expansion the potential for price competition has improved.

November 14, 2019

As the first targeted therapy in bladder cancer, erdafitinib (Balversa) expands the limited treatment options for the subset of patients with urothelial carcinoma.

November 14, 2019

During a recent OncLive Peer Exchange® program, a panel of leukemia experts provided an overview of these agents and shared their perspectives on how clinicians can incorporate them into their clinical practice.

November 13, 2019

Rapid advancements are dramatically changing the lung cancer treatment landscape, creating challenges across the spectrum of care.

November 13, 2019

The often intense and frequently highly focused effort to seek scientific purity in answering questions within cancer clinical trials raises serious concerns regarding the ethical foundation of certain studies.

November 13, 2019

Imaging approaches and technologies have advanced dramatically since the last such guidance was developed a decade ago, driving earlier and more effective detection and treatment.